PL2961426T3 - Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g - Google Patents

Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g

Info

Publication number
PL2961426T3
PL2961426T3 PL14714815T PL14714815T PL2961426T3 PL 2961426 T3 PL2961426 T3 PL 2961426T3 PL 14714815 T PL14714815 T PL 14714815T PL 14714815 T PL14714815 T PL 14714815T PL 2961426 T3 PL2961426 T3 PL 2961426T3
Authority
PL
Poland
Prior art keywords
oxygening
immunoglobulin
disorders
treatment
nervous system
Prior art date
Application number
PL14714815T
Other languages
English (en)
Inventor
William H. Frey
Leah Ranae Bresin Hanson
Sharon Pokropinski
Francisco M. Rausa Iii
Original Assignee
Baxalta GmbH
Baxalta Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Incorporated filed Critical Baxalta GmbH
Publication of PL2961426T3 publication Critical patent/PL2961426T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
PL14714815T 2013-02-26 2014-02-25 Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g PL2961426T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361769673P 2013-02-26 2013-02-26
US201361862814P 2013-08-06 2013-08-06
PCT/US2014/018426 WO2014134070A1 (en) 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
EP14714815.9A EP2961426B1 (en) 2013-02-26 2014-02-25 Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Publications (1)

Publication Number Publication Date
PL2961426T3 true PL2961426T3 (pl) 2020-02-28

Family

ID=50424697

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14714815T PL2961426T3 (pl) 2013-02-26 2014-02-25 Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g

Country Status (13)

Country Link
US (5) US9556260B2 (pl)
EP (2) EP2961426B1 (pl)
JP (1) JP6379113B2 (pl)
AU (2) AU2014223679B2 (pl)
DK (1) DK2961426T3 (pl)
ES (1) ES2759226T3 (pl)
HR (1) HRP20192111T1 (pl)
HU (1) HUE046752T2 (pl)
LT (1) LT2961426T (pl)
PL (1) PL2961426T3 (pl)
PT (1) PT2961426T (pl)
SI (1) SI2961426T1 (pl)
WO (1) WO2014134070A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150100042A1 (en) * 2013-10-07 2015-04-09 Impel Neuropharma Inc. Muroid Family Nasal Device
EP3129013A1 (en) * 2014-04-10 2017-02-15 Crowley, Patrick Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング,インコーポレイテッド Tim-3とそのリガンドとの相互作用の遮断によるがん治療
US11331270B2 (en) 2017-08-20 2022-05-17 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
WO2020163815A1 (en) * 2019-02-07 2020-08-13 Innomed Technologies, Inc. Ivig treatments for bell's palsy
EP3990440A4 (en) * 2019-06-28 2022-09-07 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF DISEASES OF THE NEUROMYELITIS OPTICA SPECTRUM
CA3148026A1 (en) * 2019-08-13 2021-02-18 Vyjayanthi Krishnan Therapeutic agent effectiveness and its route of administration
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP3991573A1 (de) * 2020-11-03 2022-05-04 Patrick Faber Zusammensetzungen zur nasalen applikation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (pl) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
WO1996022802A1 (en) 1995-01-23 1996-08-01 Direct-Haler A/S An inhaler
MXPA01008849A (es) 1999-03-03 2003-07-21 Optinose As Dispositivo de administracion nasal.
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
CA2598666A1 (en) 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
JP5697847B2 (ja) * 2006-01-30 2015-04-08 グリフオルス・セラピユーテイクス・インコーポレーテツドGrifols Therapeutics,Inc. IgMを使用する治療方法および予防方法
US20090317324A1 (en) * 2006-02-15 2009-12-24 Ramot At Tel Aviv University Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2008154337A1 (en) 2007-06-08 2008-12-18 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
EP2257804B1 (en) * 2008-02-29 2013-12-11 Baxter International Inc. Anti-amyloid activity of intravenous immunoglobulin (ivig) in vitro
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
EP2531218B1 (en) 2010-02-04 2018-12-12 CSL Behring AG Immunoglobulin preparation
US8772462B2 (en) * 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide

Also Published As

Publication number Publication date
US10144776B2 (en) 2018-12-04
EP2961426B1 (en) 2019-10-30
DK2961426T3 (da) 2019-12-02
US20240117025A1 (en) 2024-04-11
US20190055307A1 (en) 2019-02-21
US20210101967A1 (en) 2021-04-08
PT2961426T (pt) 2019-12-09
WO2014134070A1 (en) 2014-09-04
AU2014223679A1 (en) 2015-09-24
EP3597220A1 (en) 2020-01-22
LT2961426T (lt) 2019-12-27
ES2759226T3 (es) 2020-05-08
US20140242067A1 (en) 2014-08-28
EP2961426A1 (en) 2016-01-06
HUE046752T2 (hu) 2020-03-30
JP6379113B2 (ja) 2018-08-22
US9556260B2 (en) 2017-01-31
JP2016512490A (ja) 2016-04-28
US20170044244A1 (en) 2017-02-16
SI2961426T1 (sl) 2020-01-31
US12503501B2 (en) 2025-12-23
AU2014223679B2 (en) 2018-11-29
AU2018260883B2 (en) 2020-08-06
US11851481B2 (en) 2023-12-26
HRP20192111T1 (hr) 2020-03-20
AU2018260883A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
IL268987B (en) System for glaucoma treatment
IL271085A (en) Bacteria for the treatment of disorders
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
PL2961426T3 (pl) Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL257252A (en) Methods of treating fgf21-associated disorders
PL3060252T3 (pl) Zastosowanie cząsteczek wiążących semaforynę-4D do leczenia zaburzeń neurodegeneracyjnych
HUE059041T2 (hu) Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
HUE047719T2 (hu) Pirazolopirimidin-származékok alkalmazása PI3K-hoz kapcsolódó rendellenességek kezelésére
EP3761223C0 (en) AUTONOMOUS LANE OFFSET ADJUSTMENT
HRP20181679T1 (hr) Amidni spojevi za liječenje hiv
DK3110843T3 (da) Kombinationsterapier med anti-cd38-antistoffer
DK3065818T3 (da) Anordning til behandling af sygdomme i centralnervesystemet ved hjælp af sansestimulering
HUE043206T2 (hu) Kortisztatin-analógok gyulladásos és/vagy immunbetegségek kezelésére
DK3062811T3 (da) Angiopoietin-baserede interventioner til behandling af cerebral malaria
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
LT3250600T (lt) Autoimuninių sutrikimų gydymas cd154 antikūnais
IL263080B (en) Treatment of neurological disorders
ZA201507724B (en) The treatment of inflammatory disorders
DK2964185T3 (da) Præparater til behandlingen af søvnrelaterede luftvejslidelser
HUE042199T2 (hu) Pantotenát-származékok neurológiai rendellenességek kezelésére
SI2986325T1 (sl) Postopki zdravljenja motenj ciklusa sečnine